MET and lung adenocarcinoma: In particular, patients diagnosed with lung adenocarcinoma and MET amplification showed acquired resistances when treated with epidermal growth factor receptor (EGFR) inhibitors like Gefitinib or Erlotinib, regardless of EGFR mutation status [17, 18].